cemiplimab: Clinical Trials

77 trials of cemiplimab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

25 recruiting, 16 completed, 13 active not recruiting, 13 terminated. 77 Phase 1, 38 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 177Recruiting 25, Completed 16, Active not recruiting 13, Terminated 13, Withdrawn 4, Not yet recruiting 3, Unknown 2, Enrolling by invitation 1
Phase 238Recruiting 13, Active not recruiting 8, Terminated 7, Completed 6, Withdrawn 2, Not yet recruiting 1, Unknown 1

Follow cemiplimab: new trials by email Literature Review of cemiplimab trials Research Report on cemiplimab

Trials (filtered) newest first · largest first

All 77 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma
Actinium Ac 225 Lintuzumab, Biospecimen Collection, Cemiplimab - Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma
Phase 1Not yet recruitingNational Cancer Institute (NCI)302026-12-042026-06-12
A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma
Cemiplimab, Fianlimab - Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Phase 1Not yet recruitingMemorial Sloan Kettering Cancer Center602026-12-012026-11-03
A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma
Cemiplimab, Cemiplimab+Fianlimab Fixed Dose Combination (FDC) - High-Grade Glioma (HGG), Posterior Fossa-A Ependymoma
Phase 1 / Phase 2Not yet recruitingRegeneron Pharmaceuticals1202026-08-312026-05-05
Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer
Biopsy Procedure, Biospecimen Collection, Cemiplimab - Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)862026-08-102026-09-09
REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
REGN15505, REGN15505+Cemiplimab, REGN15505+REGN4336 - Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
Phase 1 / Phase 2RecruitingRegeneron Pharmaceuticals2652026-07-202026-09-28
5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors
5 Azacytidine, Pembrolizumab, Nivolumab - Solid Tumor, Locally Advanced Solid Tumor
Phase 1RecruitingMohammed Milhem352026-02-112026-05-28
Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma
cemiplimab, Topical imiquimod - Cutaneous Basal Cell Carcinoma
Phase 1 / Phase 2RecruitingInstituto Oncológico Dr Rosell182025-10-222025-12-01
A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC
REGN5678, Cemiplimab - Prostate Cancer
Phase 1RecruitingM.D. Anderson Cancer Center602025-07-092026-08-14
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
Cemiplimab, XL092 - Anaplastic Thyroid Cancer, Thyroid Cancer
Phase 1RecruitingUNC Lineberger Comprehensive Cancer Center122025-06-032026-10-05
A Phase 1 Study of BHV-1530 in Advanced Solid Tumors
BHV-1530, Cemiplimab - Solid Tumor
Phase 1RecruitingBiohaven Therapeutics Ltd.1402025-03-202026-07-09
BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd Cutaneous T-cell Lymphoma
Cemiplimab - Mycosis Fungoides
Phase 1 / Phase 2WithdrawnAHS Cancer Control Alberta2024-12-012025-06-27
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
Dupilumab, Cemiplimab - Non-Small Cell Lung Cancer
Phase 1 / Phase 2RecruitingIcahn School of Medicine at Mount Sinai212024-10-092026-07-21
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
REGN10597, Cemiplimab - Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC)
Phase 1 / Phase 2RecruitingRegeneron Pharmaceuticals2402024-09-232026-04-28
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
Cetuximab, Cemiplimab, Adagrasib - Metastatic Colorectal Cancer, KRAS G12C Mutations
Phase 1 / Phase 2RecruitingM.D. Anderson Cancer Center312024-08-282026-06-26
Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
S095018, S095024, S095029 - Non-small Cell Lung Cancer (NSCLC)
Phase 1 / Phase 2Active not recruitingServier Bio-Innovation LLC1022024-08-072026-11-12
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
27T51, Cemiplimab, Bevacizumab - Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma
Phase 1RecruitingRegeneron Pharmaceuticals902024-08-062026-02-03
Trial of INI-4001 in Patients With Advanced Solid Tumours
INI-4001, Nivolumab, Pembrolizumab - Advanced Solid Tumor
Phase 1CompletedInimmune Corporation102024-07-012026-10-16
A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors
BHV-1510, Cemiplimab - Solid Tumor
Phase 1 / Phase 2RecruitingBiohaven Therapeutics Ltd.5002024-04-222026-09-28
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
tolododekin alfa, Cemiplimab - Advanced Solid Tumor, Cutaneous Tumor
Phase 1RecruitingAnkyra Therapeutics, Inc972024-01-192026-03-06
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Biopsy, Biospecimen Collection, Bone Marrow Biopsy - Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma
Phase 1RecruitingMayo Clinic212024-01-052026-07-01

Showing 20 of 77. Sign in to see all of them.

Conditions studied

Carcinoma, Non-Small-Cell Lung (15)  ·  Neoplasm Metastasis (12)  ·  Neoplasms (11)  ·  Melanoma (10)  ·  Ovarian Neoplasms (7)  ·  Prostatic Neoplasms (7)  ·  Head and Neck Neoplasms (6)  ·  Recurrence (6)  ·  Squamous Cell Carcinoma of Head and Neck (6)  ·  Breast Neoplasms (5)  ·  Carcinoma, Renal Cell (5)  ·  Colorectal Neoplasms (5)  ·  Skin Neoplasms (4)  ·  Triple Negative Breast Neoplasms (4)  ·  Endometrial Neoplasms (3)

Sponsors

Regeneron Pharmaceuticals (22)  ·  Sanofi (6)  ·  M.D. Anderson Cancer Center (4)  ·  BioNTech SE (2)  ·  Biohaven Therapeutics Ltd. (2)  ·  Dana-Farber Cancer Institute (2)  ·  Mayo Clinic (2)  ·  Memorial Sloan Kettering Cancer Center (2)  ·  National Cancer Institute (NCI) (2)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (2)  ·  OncoResponse, Inc. (2)  ·  AHS Cancer Control Alberta (1)  ·  Ankyra Therapeutics, Inc (1)  ·  Bolt Biotherapeutics, Inc. (1)  ·  EMD Serono Research & Development Institute, Inc. (1)

Countries

United States (63)  ·  Spain (19)  ·  Australia (14)  ·  France (13)  ·  Netherlands (10)  ·  South Korea (10)  ·  United Kingdom (10)  ·  Italy (8)  ·  Belgium (7)  ·  Germany (7)  ·  Canada (6)  ·  Brazil (4)  ·  Hungary (4)  ·  Israel (4)  ·  Taiwan (4)

Top investigators

Adam Dicker, MD (1)  ·  Aixa E Soyano Muller, MD (1)  ·  Alison O'Neill, MD (1)  ·  Bilal Siddiqui, MD (1)  ·  Christine Parseghian, MD (1)  ·  Cynthia Gay, MD (1)  ·  David A Reardon, MD (1)  ·  Debika Bhattacharya, MD (1)  ·  Douglas McNeel, MD (1)

Results publications

PMID 35175355, PMID 27879972, PMID 29863979, PMID 32554615, PMID 33146741, PMID 33224628, PMID 33477979, PMID 33831732, PMID 33929394, PMID 33942954, PMID 35058326, PMID 36821617, PMID 36898933, PMID 37315579, PMID 38252908, PMID 38449916, PMID 38898592, PMID 38900987, PMID 39422598, PMID 39652449, PMID 40152791, PMID 40713179, PMID 40852760, PMID 41022754, PMID 41781018, PMID 42173654

NIH funding

2017 (3), 2018 (3), 2023 (3), 2025 (3), 2015 (2), 2016 (2), 2019 (2), P50CA186781 (2), R01CA262613 (2), P30CA014089 (1), P30CA068485 (1), P30CA138292 (1), P50CA269011 (1), UM1CA186690 (1), UM1CA186691 (1)